Go to
JCI Insight
Citations to this article
A S Brickman, … , S G Massry, A W Norman
Published June 1, 1976
Citation Information: J Clin Invest. 1976;57(6):1540-1547. https://doi.org/10.1172/JCI108424.
Citation Information: J Clin Invest. 1976;57(6):1540-1547. https://doi.org/10.1172/JCI108424.
Abstract
The effects of short-term treatment with 1,25-dihydroxy-vitamin D3 [1,25(0H)2D3] or 1 alpha-hydroxy-vitamin D3 [1 alpha(OH)D3] on intestinal absorption of 47Ca were compared in 41 experiments in normals and 72 experiments in patients with chronic renal failure. 11 patients were studied a second time after treatment for 2-5 mo. Doses varied from 0.14 to 5.4 mug/day to establish dose-response relationships. Urinary calcium was monitored in normal subjects, nine of whom received a constant calcium intake on a metabolic unit. There was an increase in intestinal absorption of 47Ca and urinary calcium in normals receiving 1,25 (OH)2D3, 0.14 mug/day or greater, and 0.28 mug/day or greater augmented intestinal absorption of 47Ca in chronic renal failure. In contrast, 2.6 mug/day of 1 alpha (OH) D3 was required to increase intestinal absorption of 47Ca in both groups. The increase in urinary calcium to maximal levels was delayed during treatment with 1 alpha (OH) D3, 5-10 days vs. 2-5 days with 1,25 (OH)2D3. Moreover, half times for urinary calcium to decrease to pretreatment levels after stopping treatment were greater after 1 alpha-(OH) D3 (1.5-2.7 days) than 1,25(OH)2D3 (1.1-2.0 days). With long-term administration there was a progressive increase in intestinal absorption of 47Ca in the patients receiving 1 alpha (OH)D3; this was not observed with 1,25(OH)2D3. The pharmacologic differences between 1 alpha(OH) D3 and 1,25(OH)2D3 may be explained by the requirement for 25-hydroxylation of 1alpha(OH) D3 before biologic effects occur; at low doses (less than 1 mug/day), 1 alpha(OH) D3 competes with vitamin D3 for 25-hydroxylation. With prolonged treatment or larger doses (greater than 2 mug/day),, 1alpha(OH) D3 could accumulate and then be hydroxylated resulting in production of higher levels of 1,25(OH)2D3.
Authors
A S Brickman, J W Coburn, G R Friedman, W H Okamura, S G Massry, A W Norman
Total citations by year
Citation information
Citations to this article (61)
| Title and authors | Publication | Year |
|---|---|---|
|
Implications of Vitamin D Research in Chickens can Advance Human Nutrition and Perspectives for the Future
MF Warren, KA Livingston |
2021 | |
|
Medical and Surgical Treatment of Parathyroid Diseases
WA Hashem, CJ Orr, AA Khan |
Medical and Surgical Treatment of Parathyroid Diseases | 2017 |
|
Chronic Renal Disease
P Delanaye, AD Rule |
2015 | |
|
Oral Vitamin D, still a viable treatment option for psoriasis
F Kamangar, J Koo, MM Heller, E Lee, T Bhutani |
Journal of Dermatological Treatment | 2011 |
|
Hypercalcemia Due to Vitamin D Toxicity
NE Cusano, S Thys-Jacobs, JP Bilezikian |
Vitamin D | 2011 |
|
Clinical management of disturbances of calcium and phosphate metabolism in dialysis patients
H Eddington, JG Heaf |
NDT Plus | 2009 |
|
Hypocalcemia and Tetany Caused by Vitamin D Deficiency in a Child With Intestinal Lymphangiectasia
YY Lu, JF Wu, YH Ni, SS Peng, S Chia-Tung, MH Chang |
Journal of the Formosan Medical Association | 2009 |
|
Up-Regulation of Transporters and Enzymes by the Vitamin D Receptor Ligands, 1α,25-Dihydroxyvitamin D 3 and Vitamin D Analogs, in the Caco-2 Cell Monolayer
J Fan, S Liu, Y Du, J Morrison, R Shipman, KS Pang |
The Journal of pharmacology and experimental therapeutics | 2009 |
|
Comprehensive Pediatric Nephrology
R Gbadegesin, WE Smoyer |
Comprehensive Pediatric Nephrology | 2008 |
|
Comparison between 1α(OH)D<sub>3</sub> and 1,25(OH)<sub>2</sub>D<sub>3</sub> on the Suppression of Plasma PTH Levels in Uremic Patients, Evaluated by the ‘Whole’ and ‘Intact’ PTH Assays
L Brandi, M Egfjord, K Olgaard |
Nephron Clinical Practice | 2005 |
|
Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4
JW Coburn, HM Maung, L Elangovan, MJ Germain, JS Lindberg, SM Sprague, ME Williams, CW Bishop |
American Journal of Kidney Diseases | 2004 |
|
An update on vitamin D as related to nephrology practice: 2003
JW Coburn |
Kidney International | 2003 |
|
Vitamin D Analogs in Cancer Prevention and Therapy
J Reichrath, W Tilgen, M Friedrich |
2003 | |
|
Short-term calcitriol administration improves calcium homeostasis in adults with cystic fibrosis
RK Lark, MB Hensler, AD Blackwood, MJ Caminiti, DC Backlund, RM Aris, SA Brown, DA Ontjes, GE Lester |
Osteoporosis International | 2003 |
|
Effects of vitamin D metabolites on intestinal calcium absorption and bone turnover in elderly women
A Devine, SG Wilson, IM Dick, RL Prince |
The American journal of clinical nutrition | 2002 |
|
Conversion of calcitriol to 1-α-hydroxy vitamin D3 in the treatment of peritoneal dialysis patients with renal osteodystrophy
CC SZETO, KM CHOW, AK WU, TY WONG, AY WANG, PK LI, SF LUI, CB LEUNG |
Hong Kong Journal of Nephrology | 2001 |
|
Current Medical Management of Secondary Hyperparathyroidism
M Yudd, F Llach |
The American Journal of the Medical Sciences | 2000 |
|
What is the optimal regimen for vitamin D?
J Cunningham |
Kidney International | 1999 |
|
Calcium Absorptive Effects of Vitamin D and Its Major Metabolites1
RP Heaney, MJ Barger-Lux, MS Dowell, TC Chen, MF Holick |
The Journal of clinical endocrinology and metabolism | 1997 |
|
Vitamin D receptor alleles and rates of bone loss: Influences of years since menopause and calcium intake
EA Krall, P Parry, JB Lichter, B Dawson-Hughes |
Journal of Bone and Mineral Research | 1995 |
|
Biological activities of 24-fluoro-1α,25-dihydroxyvitamin D-2 and its 24-epimer
I Yuko, M Akihiko, Y Norio, I Yoshiko, S Toshimasa, A Etsuko, S Tatsuo, K Katsuhiro, T Hiroaki, Y Sachiko |
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism | 1994 |
|
Intramuscular calcitriol for uraemic children with severe hyperparathyroidism and hypercalcaemia
A Claris-Appiani, GL Ardissino, MC Tischer, A Bettinelli, AS Tirelli, V Dacc, G Castiglioni, F Pecchio, M Cunazza, BM Assael |
Pediatric Nephrology | 1994 |
|
Serum ionized calcium, as well as phosphorus and parathyroid hormone, is associated with the plasma 1,25-dihydroxyvitamin D3 concentration in normal postmenopausal women
B Dawson-Hughes, S Harris, GE Dallal |
Journal of Bone and Mineral Research | 1991 |
|
Vitamin D
A Portale, Β Halloran, E Lonergan, R Morris |
Vitamin D | 1988 |
|
Clinical Disorders of Membrane Transport Processes
TE Andreoli, JF Hoffman, DD Fanestil, SG Schultz |
1987 | |
|
Treatment of psoriasis vulgaris by oral administration of 1α-hydroxyvitamin D3—Open-design study
S Morimoto, K Yoshikawa, T Kozuka, Y Kitano, S Imanaka, K Fukuo, E Koh, T Onishi, Y Kumahara |
Calcified Tissue International | 1986 |
|
The comparative toxicity of vitamin D metabolites in the weanling mouse
JF Crocker, SF Muhtadie, DC Hamilton, DE Cole |
Toxicology and Applied Pharmacology | 1985 |
|
Biliary excretion of radioactivity after intravenous administration of 3H-1,25-dihydroxyvitamin D3 in man
JE Ledger, GJ Watson, CC Ainley, JE Compston |
Gut | 1985 |
|
Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency
AA Portale, BE Booth, BP Halloran, RC Morris |
Journal of Clinical Investigation | 1984 |
|
24,25(OH)2D3, bone formation, and bone resorption in vitamin D-deficient, azotemic rats
WG Goodman, DJ Baylink, DJ Sherrard |
Calcified Tissue International | 1984 |
|
Administration of 1,25-dihydroxyvitamin D3 results in the elevation of hippocampal seizure threshold levels in rats
A Siegel, L Malkowitz, MJ Moskovits, S Christakos |
Brain Research | 1984 |
|
Studies on the mode of action of vitamin D XXXVII 1α-hydroxyvitamin D3: A long-acting 1,25-dihydroxyvitamin D3 analog
MR Walters, W Hunziker, JE Bishop, AW Norman |
Calcified Tissue International | 1983 |
|
Dünndarm A
F Bazzoli, R Böhmer, WF Caspary, H Dombrowski, B Eckhardt, B Elsenhans, A Encke, A Ferguson, W Forth, H Fromm, A Gangl, S Gutschmidt, U Hopfer, GJ Kreijs, B Lembcke, KH zum Büschenfelde, G Mödder, G Nell, HF Otto, H Peerenboom, G Rehner, G Rettenmaier, EO Riecken, JW Robinson, K Rommel, H Ruppin, J Seifert, KH Soergel, S Strobel, L Vollrath, R Wanitschke, HJ Weis |
1983 | |
|
Nephrology Forum
JJ Cohen, JT Harrington, JP Kassirer |
1983 | |
|
Effect of low dose 1 alpha-hydroxycholecalciferol on glomerular filtration rate in moderate renal failure
FU Eke, MH Winterborn |
Archives of disease in childhood | 1983 |
|
Effects of calcitriol administration on calcium metabolism in healthy men
ND Adams, RW Gray, J Lemann, HS Cheung |
Kidney International | 1982 |
|
1,25-Dihydroxyvitamin D3: short- and long-term effects on bone and calcium metabolism in patients with postmenopausal osteoporosis
JC Gallagher, CM Jerpbak, WS Jee, KA Johnson, HF DeLuca, BL Riggs |
Proceedings of the National Academy of Sciences | 1982 |
|
Disorders of Mineral Metabolism
RK Rude, FR Singer |
Disorders of Mineral Metabolism | 1982 |
|
Treatment of renal osteodystrophy with 1,25-dihydroxycholecalciferol
C Velentzas, DG Oreopoulos, A Pierratos, HE Meema, S Rabinovich, H Meindok, H Husdan, TM Murray, R Ogilvie, A Katirtzoglou |
Canadian Medical Association journal | 1981 |
|
Hypercalcaemia in alphacalcidol therapy
CR Paterson |
Postgraduate medical journal | 1981 |
|
Pharmacology and Therapeutic Use of Vitamin D and its Analogues:
AM Pierides |
Drugs | 1981 |
|
Renal osteodystrophy
JW Coburn |
Kidney International | 1980 |
|
Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy
SG Massry, DA Goldstein, HH Malluche |
Kidney International | 1980 |
|
24R,25-dihydroxyvitamin D3 and 1α,25-dihydroxyvitamin D3 are both indispensable for calcium and phosphorus homeostasis
AW Norman, HL Henry, HH Malluche |
Life Sciences | 1980 |
|
Renale Osteodystrophie bei Kindern Therapieversuch mit 1,25-Dihydroxy-Cholecalciferol
M Bulla, G Delling, G Benz-Bohm, GJ Stock, AS de Reutter, R Ziegler, H Lhmann, M Severin, E Kalbitzer, C Manegold |
Klinische Wochenschrift | 1980 |
|
Pharmakotherapie bei Niereninsuffizienz
A Heidland, E Wetzels |
1980 | |
|
The calciuria of increased fixed acid production in humans: Evidence against a role for parathyroid hormone and 1,25(OH)2-vitamin D
ND Adams, RW Gray, J Lemann |
Calcified Tissue International | 1979 |
|
Ions–Cyclic Nucleotides–Cholinergy
G Milhaud |
Ions–Cyclic Nucleotides–Cholinergy | 1979 |
|
Replacement of Renal Function by Dialysis
W Drukker, FM Parsons, JF Maher |
1979 | |
|
Bone Mineral Content in Chronic Renal Failure during Long-Term Treatment with 1α-Hydroxycholecalciferol
S Madsen, K ølgaard, J Ladefoged |
Acta Medica Scandinavica | 1978 |
|
Effect of synthetic vitamin D derivatives on calcium and phosphate metabolism in intact vitamin O-replete rats
JP Bonjour, R Rizzoli, K Hugi, B Haldimann, H Fleisch |
Metabolic Bone Disease and Related Research | 1978 |
|
Effect of 25-hydroxy-vitamin D3 on intestinal absorption of calcium in normal man and patients with renal failure
IH Colodro, AS Brickman, JW Coburn, TW Osborn, AW Norman |
Metabolism | 1978 |
|
Vitamin D Physiology and Some Clinical Aspects of the Vitamin D Endocrine System
MJ Favus |
Medical Clinics of North America | 1978 |
|
Homeostasis of Phosphate and Other Minerals
SG Massry, E Ritz, A Rapado |
1978 | |
|
Physiology of Membrane Disorders
TE Andreoli, JF Hoffman, DD Fanestil |
1978 | |
|
The Year in Metabolism 1977
N Freinkel |
1978 | |
|
Clinical use of 1-alpha-hydroxyvitamin D3.
|
British medical journal | 1978 |
|
BONE DISEASE AND H YPERP AR ATH YROI DISM IN CHRONIC RENAL FAILURE: THE EFFECT OF lα-HYDROXYVITAMIN D3
M Peacock, JE Aaron, GS Walker, AM Davison |
Clinical Endocrinology | 1977 |
|
Nutritional supplements in renal failure
KH Stenzel |
The American Journal of Medicine | 1977 |
|
Basic and Clinical Concepts Related to Vitamin D Metabolism and Action
MR Haussler, TA McCain |
New England Journal of Medicine | 1977 |
|
25-Hydroxyvitamin D3 regulation
MB Clark, JT Potts |
Calcified Tissue Research | 1976 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)